Gene Panel Market By Type of Panel (Diagnostic Panels, Carrier Screening Panels, Pharmacogenomics Panels, Cancer Panels), Application (Clinical Applications, Research Applications), Technology (Next-Generation Sequencing (NGS) Panels, Polymerase Chain Reaction (PCR) Panels) & Region for 2024-2031

Gene Panel Market Valuation – 2024-2031

The rapid advancement of genetic technologies and personalized medicine. As the cost of genomic sequencing has decreased, gene panels have become more affordable, allowing for thorough genetic testing and analysis of a wide range of disorders. This expansion is accelerated by the increased prevalence of genetic illnesses and the growing desire for accurate, tailored treatment regimens market growth surpassing USD 3660.09 Million in 2024 and reaching USD 14408.16 Million by 2031.

Furthermore, the increasing use of gene panels in research, diagnostics, and therapeutic development is driving market expansion, as they provide useful insights into genetic predispositions and prospective treatment choices is expected to grow at a CAGR of about 20.61% from 2024 to 2031.

Gene Panel MarketDefinition/ Overview

A gene panel is a group of genes that are studied together to detect genetic variants linked to specific diseases or situations. Gene panels are used in diagnostic testing for genetic disorders, customized treatment, and disease research. They allow for targeted and efficient study of several genes at the same time, providing insights into inherited disorders and aiding in the development of specific treatment regimens. The future of gene panels is broad, with ongoing advances in sequencing technologies and bioinformatics poised to improve their precision and applicability, driving their integration into routine clinical practice and expanding their use in both preventive and therapeutic settings.

Will Rapid Advancements in Genomic Technologies and Personalized Medicine Drive the Gene Panel Market?

Rapid breakthroughs in genomics and customized treatment are propelling the gene panel market. As genomic sequencing technology advance, they become more cost-effective and efficient, making gene panels available to a larger population. Innovations like next-generation sequencing (NGS) and enhanced bioinformatics tools improve genetic testing accuracy and efficiency. This advancement enables concurrent study of numerous genes, providing detailed insights into hereditary disorders and supporting individualized treatment plans. For example, advances in high-throughput sequencing and data processing allow for more exact identification of genetic variations associated with diseases, resulting in more targeted and successful therapeutic interventions.

The demand for personalized therapy is another important reason driving the gene panel industry. Personalized medicine focuses on adapting healthcare treatments to individual genetic profiles, which demands extensive genetic information from gene panels. As healthcare practitioners embrace more tailored approaches, the demand for detailed genetic data increases, boosting the use of gene panels. Personalized medicine not only improves patient outcomes by identifying the most effective medicines based on genetic information, but it also aids in illness prediction and early detection. This shift toward customized healthcare models is driving the gene panel industry, as healthcare providers and researchers attempt to use genetic insights to improve patient care.

For instance, in June 2024, Illumina announced the debut of its new genome sequencing technology, which is intended to improve gene panel analysis with better accuracy and speed. This technology aims to lower the cost of genetic testing while improving data quality, making gene panels more accessible for clinical and research use.

Similarly, in April 2024, Thermo Fisher Scientific launched a new line of gene panels designed for personalized therapy, with a focus on uncommon and difficult disorders. These developments highlight the ongoing advancements in genomic technologies and their significance in propelling the gene panel market ahead, demonstrating the expanding integration of advanced genetic tools into healthcare and research.

Will Increasing Difficulties in Interpreting the Data Hinder the Gene Panel Market?

Increasing problems in interpreting gene panel data may represent a hindrance to the expansion of the gene panel market. Gene panels provide massive volumes of complex data since they investigate numerous genes at the same time. To distinguish between clinically relevant and benign variations, modern bioinformatics techniques and experience are required for data interpretation. The complexity of genetic information, as well as the necessity for exact interpretation, can impede the process of gaining actionable insights, possibly restricting the efficiency of gene panels in clinical settings. For instance, distinguishing between harmful mutations and polymorphisms can be difficult, and errors in interpretation might result in inaccurate diagnosis or wrong treatment recommendations.

The gene panel market is primarily reliant on specialized bioinformaticians and geneticists to analyze and interpret the data. However, there is a growing demand for such expertise, which frequently exceeds supply, resulting in possible bottlenecks in the process. Furthermore, the lack of widely agreed criteria for analyzing gene panel data contributes to inconsistency in outcomes and may impede gene panel adoption across various healthcare settings. Without defined standards, healthcare providers may struggle to interpret data consistently, reducing the reliability and acceptability of gene panels.

In May 2024, the American College of Medical Genetics and Genomics (ACMG) released updated guidelines intended at enhancing the evaluation of genetic variations discovered using gene panels. These guidelines establish a framework for standardized data interpretation, thereby mitigating some of the complications inherent with gene panel data. Furthermore, companies such as Illumina and Thermo Fisher Scientific are investing in advanced bioinformatics tools to improve data analysis and interpretation, perhaps alleviating some of the issues. These advances are critical to ensure that gene panels continue to be a valuable tool in precision medicine and genetic research, despite the inherent problems in data interpretation.

Category-Wise Acumens

Will Rising Demand for Cancer Panels Drive the Gene Panel Market?

The growing need for cancer panels is projected to propel the gene panel industry. Cancer panels are useful in detecting genetic mutations and changes associated with various malignancies. These panels allow for early detection, accurate diagnosis, and the creation of tailored treatment programs. As the global cancer incidence continues to climb, there is a growing demand for sophisticated diagnostic instruments capable of providing complete genetic analysis. Cancer panels are meant to test numerous genes at once, offering crucial insights that can lead to more effective and targeted cancer treatments. This increasing demand for cancer panels is consistent with the broader trend of personalized medicine, in which treatment tactics are matched to an individual’s genetic profile.

For instance, in April 2024, Illumina launched their new “TruSight Oncology 500” panel, which uses next-generation sequencing (NGS) to conduct in-depth analyses of over 500 cancer-related genes. This breakthrough intends to increase the accuracy and comprehensiveness of cancer genetic testing, providing doctors and researchers with better diagnostic capabilities.

Similarly, in June 2024, Thermo Fisher Scientific added the “Oncomine Comprehensive Assay v4,” a new cancer panel designed to support a variety of cancer research and clinical applications. These developments demonstrate the increased emphasis on upgrading cancer panels to address the growing demand for precise and actionable genomic information.

The emphasis on personalized oncology and targeted medicines is also helping to drive the cancer panel industry. Healthcare professionals are increasingly using personalized medicine approaches to adapt cancer therapies based on patients’ genetic profiles. This trend is visible in recent agreements, such as the one announced in March 2024 by Guardant Health and the Mayo Clinic, which aims to integrate liquid biopsy technology and full cancer panels into clinical practice. This partnership emphasizes the importance of cancer panels in developing precision oncology, as well as how increased demand for individualized cancer care is driving the gene panel business. As more healthcare systems and research institutes focus on tailored and targeted therapeutics, demand for advanced cancer panels is expected to continue rising, further propelling market expansion.

Pharmacogenomics panels are the fastest-growing market, owing to the growing emphasis on customized treatment and targeted pharmacological therapy. Pharmacogenomics panels are fast gaining attention as healthcare professionals and academics focus on maximizing drug efficacy and avoiding unwanted effects based on genetic profiles, echoing the broader trend toward personalized treatment options.

Will Increasing Adoption of Next-Generation Sequencing Panels Technology Fuel the Gene Panel Market?

The increasing use of next-generation sequencing (NGS) panels is likely to drive the gene panel market. NGS technology has transformed genetic testing by allowing for simultaneous study of numerous genes, providing detailed insights into genetic variants associated with various disorders. This capability improves diagnosis accuracy and personalizes medicine by allowing for more targeted and effective treatment approaches. The capacity of NGS panels to produce high-throughput, high-resolution data is pushing their broad use in clinical and research settings. As healthcare practitioners and academics increasingly grasp the benefits of NGS in providing accurate genetic information, demand for NGS panels rises, moving the gene panel market ahead.

For instance, in April 2024, Illumina introduced the “NovaSeq X Plus” system, an enhanced NGS platform intended to speed up genomic research and clinical diagnostics. This novel technology improves data quality and provides faster turnaround times, making it an important tool for high-throughput genetic analysis.

Personalized medicine uses extensive genetic information to adapt therapies to specific patients, boosting outcomes while minimizing side effects. Guardant Health and the Mayo Clinic established a cooperation in March 2024, with the goal of bringing NGS-based liquid biopsy panels into standard clinical practice. This cooperation intends to improve cancer diagnosis and treatment personalization, demonstrating the growing integration of NGS technology into healthcare systems. As precision medicine gains popularity, demand for NGS panels is likely to climb, confirming their role in influencing the future of genetic testing and driving growth in the gene panel market.

PCR panels are gaining popularity due to their low cost and quick turnaround time. Although PCR technology is typically employed for more specific gene analysis, its growing use in common diagnostic procedures and research is fueling its rapid expansion. This trend reflects an increasing need for innovative and affordable genetic testing options in a variety of clinical and research contexts.

Gain Access into Gene Panel Market Report Methodology

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Gene Panel Market?

The improved healthcare infrastructure in North America is propelling the gene panel industry. The region is distinguished by advanced medical facilities, extensive use of cutting-edge technologies, and a strong network of research institutions. The availability of sophisticated diagnostic equipment and well-established healthcare systems makes gene panel testing more easily integrated into ordinary clinical practice. This acceptance is further aided by significant investments in genomics research made by both the public and corporate sectors. For instance, the National Institutes of Health (NIH) in the United States continues to finance a variety of genomic initiatives, advancing the development and use of gene panels in personalized medicine.

Furthermore, the presence of large biotechnology and pharmaceutical businesses in North America has accelerated the expansion of the gene panel industry. These firms are constantly innovating and enhancing gene panel technology to suit the growing need for accurate and comprehensive genetic testing. For instance, in June 2023, Illumina, a leading biotechnology company, announced the release of their most recent gene panel, which produces faster and more precise sequencing findings. This breakthrough is expected to improve genetic testing methods, making them more accessible and efficient for both healthcare providers and patients.

The growing prevalence of chronic diseases and genetic abnormalities in North America contributes to the demand for gene panels. As healthcare practitioners attempt to give tailored treatment regimens, proper genetic testing becomes critical. Gene panels enable the detection of genetic mutations and variants that contribute to specific diseases, allowing for more targeted treatment options.

Will Rising Awareness of Genetic Testing in Asia-Pacific Propel the Gene Panel Market?

Rising awareness of genetic testing in Asia-Pacific is considerably driving the gene panel market. The growing acknowledgment of genetic testing’s importance in detecting and treating numerous genetic illnesses has resulted in an increase in demand for gene panels. Countries such as China, Japan, and India are leading the way, with governments and healthcare organizations actively encouraging genetic testing. This increased awareness is fueling market expansion as more healthcare professionals use gene panel technology to give individualized medical treatments based on individual genetic profiles.

In April 2024, the Chinese government launched a new push to incorporate genetic testing into routine medical check-ups, with the goal of early detection and management of genetic illnesses. This program is projected to generate significant demand for gene panels, particularly in urban regions with advanced healthcare infrastructure. Furthermore, the Japanese government has provided large sums to assist genetic research and testing, thereby strengthening the industry. This government support is critical for boosting the adoption of gene panels in the region and making genetic testing more accessible to the general public.

Furthermore, private enterprises contribute to the market’s growth. In May 2024, Mapmygenome, an Indian genetic testing company, will expand its services to rural areas, with the goal of raising awareness and providing genetic testing to neglected communities. This move demonstrates the increased interest and investment in genetic testing in the Asia-Pacific area. As awareness grows, more people are anticipated to seek genetic testing, driving demand for gene panels and fostering market growth.

Competitive Landscape

The competitive landscape of the gene panel market, excluding key players, is characterized by a mix of emerging startups, regional companies, and specialized genetic testing firms. These companies are focusing on niche segments, such as rare genetic disorders and personalized medicine, to differentiate themselves. They are also investing in developing advanced gene panel technologies and expanding their service offerings to gain a competitive edge. Collaborations with academic institutions and research organizations are common, enabling these firms to stay at the forefront of technological advancements. Additionally, many are leveraging local market knowledge and regulatory expertise to cater to specific regional needs and preferences, thus enhancing their market presence.

Some of the prominent players operating in the gene panel market include

• Illumina
• Thermo Fisher Scientific
• Agilent Technologies
• Roche Diagnostics

Latest Developments

• In February 2024, Roche Diagnostics published an upgraded version of its hereditary cancer gene panel, which now includes over 100 genes linked to various cancer syndromes. The panel now contains newly discovered cancer-related genes and better variant interpretation capabilities.
• In April 2024, Twist Bioscience has launched a new service that allows researchers to build and order unique gene panels quickly. This service uses the company’s DNA synthesis technology to create bespoke panels for individual research needs in weeks.
• In December 2023, Qiagen has introduced a new gene panel aimed at neurological illnesses such as Alzheimer’s, Parkinson’s, and ALS. This panel intends to fund research into the genetic variables that contribute to various illnesses and aid in the development of targeted medicines.

Report Scope

Gene Panel Market, By Category

 Type of Panel

• Diagnostic Panels
• Carrier Screening Panels
• Pharmacogenomics Panels
• Cancer Panels

Application

• Clinical Applications
• Research Applications

Technology

• Next-Generation Sequencing (NGS) Panels
• Polymerase Chain Reaction (PCR) Panels

Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.